Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease

Funding Amount:
Resolution Therapeutics has raised £63.5M ($83.3M) in a Series B financing round.

Purpose of Funding:
The funds will be used to advance the company's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy, particularly for the treatment of liver disease.

Clinical Stage:
The company is at a clinical stage and aims to begin a first-in-human trial of its macrophage cell therapy for liver disease.

Therapeutic Focus:
Resolution Therapeutics focuses on developing macrophage cell therapies to treat diseases characterized by life-threatening inflammatory organ damage, including inflammatory and fibrotic diseases.

Company Background:
Resolution Therapeutics is a biopharmaceutical company dedicated to unlocking regenerative macrophage therapies for various diseases.